JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

Начало・Списък с акции・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Затворен

1.26 -0.79

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.25

Максимум

1.3

Ключови измерители
By Trading Economics
Приходи	2.7M -24M
EPS	-0.354
Служители	49
EBITDA	-5.3M -28M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+106.98% upside

Дивиденти
By Dow Jones
Следващи печалби	7.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-1.2M 80M
Предишно отваряне	2.05
Предишно затваряне	1.26

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

1.43 / 1.6 Подкрепа & съпротива

Pliant Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

24.04.2026 г., 00:00 ч. UTC

Печалби

Renesas Electronics 1Q Net Y68.15B Vs Net Y26.01B

24.04.2026 г., 00:00 ч. UTC

Печалби

Renesas Electronics 1Q Net Y68.15B Vs Net Y26.01B

23.04.2026 г., 23:47 ч. UTC

Пазарно говорене

Gold Edges Lower Amid Ongoing Concerns Over Higher Inflation -- Market Talk

23.04.2026 г., 23:43 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

23.04.2026 г., 23:43 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

23.04.2026 г., 23:43 ч. UTC

Пазарно говорене

Nikkei May Decline Amid Uncertainty Over U.S.-Iran Conflict -- Market Talk

23.04.2026 г., 23:13 ч. UTC

Придобивния, сливания и поглъщания

Trump on Spirit Airlines: 'I Think We'd Just Buy It' -- Update

23.04.2026 г., 22:33 ч. UTC

Печалби

Intel Shares Jump 20% as AI Agents Drive Big Growth -- WSJ

23.04.2026 г., 22:17 ч. UTC

Печалби

PLS Executed Offtake Agreement With Ronbay

23.04.2026 г., 22:17 ч. UTC

Печалби

PLS Secured Up to A$38.1M in Australia Government ARENA Grant Funding

23.04.2026 г., 22:16 ч. UTC

Печалби

PLS Commences Commissioning of Midstream Demonstration Plant

23.04.2026 г., 22:15 ч. UTC

Печалби

PLS Group Reaffirms FY26 Guidance for All Metrics

23.04.2026 г., 22:14 ч. UTC

Печалби

PLS Group 3Q Cash Margin From Operations A$461M at March 31

23.04.2026 г., 22:14 ч. UTC

Печалби

PLS Group 3Q Cash Balance A$1.455 Billion at March 31

23.04.2026 г., 22:13 ч. UTC

Печалби

PLS Group 3Q Unit Operating Cost A$733/Ton CIF, Up 2% on 2Q

23.04.2026 г., 22:12 ч. UTC

Печалби

Correct: PLS Group 3Q Unit Operating Cost A$520/Ton FOB, Down 11% on 2Q

23.04.2026 г., 22:12 ч. UTC

Печалби

PLS Group 3Q Unit Operating Cost US$520/Ton FOB, Down 11% on 2Q

23.04.2026 г., 22:11 ч. UTC

Печалби

PLS Group 3Q Realized Price US$1,867/Ton, Up 61% on 2Q

23.04.2026 г., 22:10 ч. UTC

Печалби

PLS Group 3Q Revenue A$567,000, Up 52% on 2Q

23.04.2026 г., 22:09 ч. UTC

Печалби

PLS Group 3Q Sales 195,700 Tons, Down 16% on 2Q

23.04.2026 г., 22:08 ч. UTC

Печалби

PLS Group 3Q Production 232,400 Tons, Up 12% on 2Q

23.04.2026 г., 22:04 ч. UTC

Печалби

Intel Sales Rise 7% as AI Agents Drive Growth -- WSJ

23.04.2026 г., 21:56 ч. UTC

Пазарно говорене

Печалби

Intel Points to Growing Role of CPUs Amid AI Shifts -- Market Talk

23.04.2026 г., 21:48 ч. UTC

Придобивния, сливания и поглъщания

Regeneron Shares Up on Trump Drug Pricing Deal -- Barrons.com

23.04.2026 г., 21:27 ч. UTC

Печалби

Intel CFO: All Demand Signals Point to Growing Role of CPUs in AI Era

23.04.2026 г., 21:25 ч. UTC

Печалби

Intel CFO Expects Factories to Continue Increasing Supply in 3Q, 4Q, but at More Measured Pace Than Previously Expected

23.04.2026 г., 21:24 ч. UTC

Печалби

SAP Stock Rebounds From Software Slaughter. The Cloud Boosted Europe's Tech Titan. -- Barrons.com

23.04.2026 г., 21:24 ч. UTC

Печалби

Blackstone Stock Falls After Earnings. Private Credit Remains in Focus. -- Barrons.com

23.04.2026 г., 21:21 ч. UTC

Печалби

Intel to Look for Unconventional Way to Boost Manufacturing Capacity Through Musk's Terafab Project, CEO Says

23.04.2026 г., 21:21 ч. UTC

Печалби

Intel CEO: He, Elon Musk Believe Global Semiconductor Supply Isn't Keeping Up With Accelerating Demand

Сравнение с други в отрасъла

Ценова промяна

Pliant Therapeutics Inc Прогноза

Ценова цел

By TipRanks

106.98% нагоре

12-месечна прогноза

Среден 2.67 USD 106.98%

Висок 3 USD

Нисък 2 USD

Според 5 анализатори от Wall Street, предложили 12-месечна ценова цел за Pliant Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

5 ratings

Купи

Задържане

Продай

Според 5 анализатори, дали борсови рейтинги на Pliant Therapeutics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

1.43 / 1.6Подкрепа & съпротива

Recent bearish events outweigh bullish events.

There is one bearish event.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.